cevimeline
Sign in to saveAlso known as Cevimelina, 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine, Sni 2011, Cevimelinum, Evoxac
Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M1 and M3 receptors. It is used in the treatment of dry mouth and Sjögren's disease.
Research
231 papers- Cevimeline.2012
- Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and Neurodegeneration.International journal of molecular sciences · 2021
- Cevimeline.Drugs · 2008
- EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.Annals of the rheumatic diseases · 2020
- Xerostomia of Various Etiologies: A Review of the Literature.Advances in clinical and experimental medicine : official organ Wroclaw Medical University · 2016
via PubMed
~1 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Side effects
- Mechanism of action
- See also
- References
- External links
Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M1 and M3 receptors. It is used in the treatment of dry mouth and Sjögren's disease.
== Medical uses == Cevimeline is used in the treatment of xerostomia (dry mouth) and Sjögren's syndrome. It increases the production of saliva.
Excerpted from Wikipedia’s “cevimeline” article, available under the CC BY-SA 4.0 licence.